Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05761951
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2023-02-27
Brief Title:
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 DKK1 Inhibitor Leap Therapeutics and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 DKK1 Inhibitor Leap Therapeutics and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer
Detailed Description:
Primary Objective
--The primary objective is to determine the efficacy objective response rate ORR of the combination of DKN-01 and pembrolizumab in the treatment of women with advanced recurrent endometrioid endometrial cancer or non-endometrioid endometrial cancer with a Wnt β-catenin activating mutation
Secondary Objective
--Estimate clinical benefit progression-free survival overall survival and duration of response in patients with recurrent or progressive EC treated with DKN-01 Pembrolizumab To assess the tolerability of the combination
Exploratory Objective
We will perform the following translational studies to determine the correlation between molecular characteristics and likelihood of response to therapy The six-month progression free survival PFS and the median survival from time of study entry first treatment to progression PFS or death OS will be estimated
Determine if DKK1 over-expression using RNAscope in situ hybridization performed in a central lab is associated with CTNNB1 mutation or mutation in other genes associated with Wntβ-catenin pathway activation High expression of DKK1 is defined as greater than 10 positive cells on RNAscope
Determine if mutation status of CTNNB1 or other genes known to result in activation of WNTβ-catenin signaling such as RNF-43 APC AXIN12 RSPO23 and ZNRF3 1 correlate to response to the combination in women with advanced or recurrent EC Mutation status of these genes will be determined by next-generation sequencing Oncomine ThermoFisher in a CLIA- and CAP-approved Molecular Diagnostics Laboratory in the Division of Pathology Laboratory Medicine MD Anderson Cancer Center using formalin-fixed paraffin-embedded tissues OR other commercially available CLIA-certified platforms including but not limited to FoundationOne Tempus or CARIS The presence of a mutation in any of these genes will be considered as indicative of Wntβ-catenin pathway activation in a patients tumor Mutation status will be correlated with treatment response Mutation status will be correlated with tumoral DKK1 expression NGS will be performed on baseline biopsies of metastatic disease at the time of enrollment when available or using the primary tumor from the hysterectomy if tissue cannot be obtained or is inadequate for testing
Determine optimal threshold of DKK1 expression and correlation to treatment response to DKN-01 and pembrolizumab
Determine if IHC nuclear localization of mutant β-catenin correlates to treatment response to DKN-01 and pembrolizumab
Determine if IHC CD73 expression levels correlate to treatment response to DKN-01 and pembrolizumab
Determine if PD-L1 IHC levels correlate to treatment response
Determine if additional genetics by NGS including but not limited to PIK3CA mutations and TMB correlate to treatment response
Determine if blood-based protein markers including but not limited to cytokines at baseline and changes on treatment correlate to response
--The primary objective is to determine the efficacy objective response rate ORR of the combination of DKN-01 and pembrolizumab in the treatment of women with advanced recurrent endometrioid endometrial cancer or non-endometrioid endometrial cancer with a Wnt β-catenin activating mutation
Secondary Objective
--Estimate clinical benefit progression-free survival overall survival and duration of response in patients with recurrent or progressive EC treated with DKN-01 Pembrolizumab To assess the tolerability of the combination
Exploratory Objective
We will perform the following translational studies to determine the correlation between molecular characteristics and likelihood of response to therapy The six-month progression free survival PFS and the median survival from time of study entry first treatment to progression PFS or death OS will be estimated
Determine if DKK1 over-expression using RNAscope in situ hybridization performed in a central lab is associated with CTNNB1 mutation or mutation in other genes associated with Wntβ-catenin pathway activation High expression of DKK1 is defined as greater than 10 positive cells on RNAscope
Determine if mutation status of CTNNB1 or other genes known to result in activation of WNTβ-catenin signaling such as RNF-43 APC AXIN12 RSPO23 and ZNRF3 1 correlate to response to the combination in women with advanced or recurrent EC Mutation status of these genes will be determined by next-generation sequencing Oncomine ThermoFisher in a CLIA- and CAP-approved Molecular Diagnostics Laboratory in the Division of Pathology Laboratory Medicine MD Anderson Cancer Center using formalin-fixed paraffin-embedded tissues OR other commercially available CLIA-certified platforms including but not limited to FoundationOne Tempus or CARIS The presence of a mutation in any of these genes will be considered as indicative of Wntβ-catenin pathway activation in a patients tumor Mutation status will be correlated with treatment response Mutation status will be correlated with tumoral DKK1 expression NGS will be performed on baseline biopsies of metastatic disease at the time of enrollment when available or using the primary tumor from the hysterectomy if tissue cannot be obtained or is inadequate for testing
Determine optimal threshold of DKK1 expression and correlation to treatment response to DKN-01 and pembrolizumab
Determine if IHC nuclear localization of mutant β-catenin correlates to treatment response to DKN-01 and pembrolizumab
Determine if IHC CD73 expression levels correlate to treatment response to DKN-01 and pembrolizumab
Determine if PD-L1 IHC levels correlate to treatment response
Determine if additional genetics by NGS including but not limited to PIK3CA mutations and TMB correlate to treatment response
Determine if blood-based protein markers including but not limited to cytokines at baseline and changes on treatment correlate to response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2023-01855 | OTHER | NCI-CTRP Clinical Trials Registry | None |